Pharmacological Reviews · Oct 15, 2026
Immunopathological mechanisms linking atherosclerosis and ischemic stroke: From microenvironmental vulnerability to precision therapeutics
By Liu W, Zou Q, Liu W et al.
Atherosclerotic ischemic stroke results from a multistage process in which systemic susceptibility and local arterial biology converge to generate plaque vulnerability, thrombosis, embolization, and cerebral ischemia. This review critically integrates experimental, human tissue, observational, imaging, and randomized clinical evidence across this continuum. We distinguish disturbed flow-induced endothelial dysfunction and intimal retention of apolipoprotein B-containing lipoproteins as upstream processes from macrophage dysfunction, defective efferocytosis, vascular smooth muscle cell remodeling, pathological neovascularization, and intraplaque hemorrhage that promote structural vulnerability. We then examine how plaque rupture and, with less direct cerebrovascular evidence, superficial erosion interact with platelet activation, coagulation, and neutrophil-associated immunothrombosis to produce artery-to-artery embolization or hemodynamic ischemia. Systemic modifiers, including clonal hematopoiesis, trained immunity, gut-derived metabolites, psychological stress, infection, and environmental exposures, are evaluated according to evidence maturity and stroke-specific relevance. Poststroke neuroimmune-hematopoietic reprogramming is considered an experimentally supported but incompletely validated feedback mechanism in humans. Among imaging-defined plaque features, carotid intraplaque hemorrhage has comparatively mature human prognostic evidence, whereas many molecular signatures remain investigational. Emerging single-cell, spatial, multiomic, molecular-imaging, and thrombus-profiling technologies are considered separately from clinically validated risk tools. Finally, therapeutic strategies are organized by mechanism and strength of clinical evidence, distinguishing established lipid-lowering, antithrombotic, and reperfusion approaches from investigational inflammatory, lipoprotein(a)-directed, and genome-editing strategies. This evidence-based framework identifies where mechanistic insight is mature, where translation remains uncertain, and how precision prevention may be advanced in atherosclerotic stroke. SIGNIFICANCE STATEMENT: Atherosclerotic ischemic stroke is driven by more than arterial narrowing: plaque vulnerability, immune inflammation, thrombosis, and impaired cerebral perfusion interact to determine clinical risk. By separating findings supported by human cerebrovascular evidence from emerging experimental mechanisms, this review clarifies opportunities and limitations for improved risk stratification, biomarker development, and mechanism-guided prevention.
doi.org/10.1016/j.pharmr.2026.100164PubMed 43050842Mechanisms